The results were consistent with those of our previous study [20], Significantly stronger and rapid inhibition of tumor progression was observed in the CART-CEA.sBsAb-treated and CART-CEA.sPD-1-treated compared with that of the CART-CEA and CART-CEA.sTREM2 scFv-treated CRC mice, as indicated by fluorescence intensity measurements. The gene discussed is HOXD13; the disease is colorectal carcinoma.